Related Experiment Video
Updated: May 14, 2026

In vitro Measurements of Tracheal Constriction Using Mice
Published on: June 25, 2012
Transdermal scopolamine attenuates methacholine-induced bronchospasm.
I Khadra1, S R Braun, G C Scott
1Division of Pulmonary, Critical Care, and Environmental Medicine, University of Missouri-Columbia 65212.
Transdermal scopolamine (TS) patches may reduce airway hyperreactivity in asthma. This study found TS significantly decreased methacholine-induced bronchospasm in mild asthma patients, suggesting a potential new treatment approach.
Area of Science:
- Pulmonology
- Pharmacology
- Allergy & Immunology
Background:
- Anticholinergic agents are common asthma treatments.
- Scopolamine's side effects have limited its use.
- Transdermal scopolamine (TS) is effective for motion sickness.
Purpose of the Study:
- To investigate if transdermal scopolamine (TS) reduces methacholine-induced bronchospasm in mild asthma.
- To assess the efficacy of TS in decreasing airway reactivity.
Main Methods:
- 10 male subjects with mild asthma underwent methacholine bronchoprovocation challenges.
- Subjects received either a placebo or TS patch in a double-blind, crossover design.
- Provocative dose for a 20% fall in FEV1 was calculated.
Main Results:
- No significant changes in baseline pulmonary function were observed with placebo or TS.
- Transdermal scopolamine (TS) showed a significant increase in the provocative dose (p < 0.05).
- TS demonstrated a decrease in airway reactivity to methacholine.
Conclusions:
- Transdermal scopolamine (TS) patches can significantly decrease airway reactivity to methacholine.
- TS may be a viable option for managing hyperactive airways in some asthma patients.
- Short-term use of TS patches shows potential therapeutic benefits for asthma.
More Related Videos
07:28Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
Related Concept Videos
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Cholinergic Antagonists: Pharmacokinetics
Cholinergic Antagonists: Pharmacological Actions
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...